We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Therapeutic Strategies for Idiopathic Pulmonary Fibrosis – Thriving Present and Promising Tomorrow.
- Authors
Gupta, Nikita; Paryani, Mitali; Patel, Snehal; Bariya, Aditi; Srivastava, Anshu; Pathak, Yashwant; Butani, Shital
- Abstract
Idiopathic pulmonary fibrosis (IPF) is a continuous, progressive, and lethal age‐related respiratory disease. It is characterized by condensed and rigid lung tissue, which leads to a decline in the normal functioning of the lungs. The pathophysiology of IPF has still not been completely elucidated, so current strategies are lagging behind with respect to improving the condition of patients with IPF and increasing their survival rate. The desire for a better understanding of the pathobiology of IPF and its early detection has led to the identification of various biomarkers associated with IPF. The use of drugs such as pirfenidone and nintedanib as a safe and effective treatment alternative have marked a new chapter in the treatment of IPF. However, nonpharmacological therapies, involving long‐term oxygen therapy, transplantation of the lungs, pulmonary rehabilitation, ventilation, and palliative care for cough and dyspnea, are still considered to be beneficial as supplementary methods for IPF therapy. A major risk factor for IPF is aging, with associated hallmarks such as telomere attrition, senescence, epigenetic drift, stem cell exhaustion, loss of proteostasis, and mitochondrial dysfunction. These are promising earmarks for the development of potential therapy for the disease. In this review, we have discussed current and emerging novel therapeutic strategies for IPF, especially for targets associated with age‐related mechanisms.
- Subjects
PALLIATIVE treatment; PROTEIN metabolism disorders; EPIGENOMICS; OXYGEN therapy; CELLULAR therapy; LUNG diseases; MEDICAL rehabilitation; ARTIFICIAL respiration; AGING; IDIOPATHIC pulmonary fibrosis; MITOCHONDRIAL pathology; STEM cells; BIOMARKERS; PHENOTYPES; DISEASE risk factors; SYMPTOMS
- Publication
Journal of Clinical Pharmacology, 2024, Vol 64, Issue 7, p779
- ISSN
0091-2700
- Publication type
Article
- DOI
10.1002/jcph.2408